Ruohua Chen1, Xiang Zhou1, Jianjun Liu2, Gang Huang3. 1. Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China Department of Cancer Metabolism, Institute of Health Sciences, Chinese Academy of Sciences, and School of Medicine, Shanghai Jiao Tong University, Shanghai, China; and. 2. Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 3. Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China Department of Cancer Metabolism, Institute of Health Sciences, Chinese Academy of Sciences, and School of Medicine, Shanghai Jiao Tong University, Shanghai, China; and Shanghai University of Medicine and Health Sciences (SUMHS), Shanghai, China huang2802@163.com.
Abstract
UNLABELLED: (18)F-FDG PET has been widely used in the management of malignant tumors. In gastric cancer, the status of human epidermal growth factor receptor 2 (HER2) predicts the response to anti-HER2 antibody therapy, and testing of HER2 expression is now routine in the management of gastric cancer patients. However, to date, the relationship between (18)F-FDG uptake and HER2 expression has not, to our knowledge, been investigated. In this study, we aimed to investigate whether HER2 expression is associated with (18)F-FDG uptake and whether (18)F-FDG PET/CT can be used to predict the HER2 status of gastric cancer. METHODS: A retrospective analysis was performed on 64 gastric cancer patients who had undergone (18)F-FDG PET/CT before surgical resection. Tumor SUVmax was calculated from the level of (18)F-FDG uptake. RESULTS: No significant correlation was found between SUVmax and HER2 expression in gastric cancer. However, when signet-ring cell carcinoma was excluded, SUVmax was significantly higher in the HER2-negative group than in the HER2-positive group (8.619 ± 5.878 vs. 3.789 ± 2.613, respectively; P = 0.021). Multivariate analysis indicated that SUVmax and tumor differentiation remained significantly associated with HER2 expression (P = 0.048 and P = 0.028, respectively). HER2 expression was predicted with an accuracy of 64.4% when an SUVmax cutoff of 6.2 was used. CONCLUSION: (18)F-FDG uptake by gastric cancer is associated with HER2 expression. (18)F-FDG PET/CT may be useful for predicting the HER2 status of gastric cancer and for determining the therapeutic strategy.
UNLABELLED: (18)F-FDG PET has been widely used in the management of malignant tumors. In gastric cancer, the status of humanepidermal growth factor receptor 2 (HER2) predicts the response to anti-HER2 antibody therapy, and testing of HER2 expression is now routine in the management of gastric cancerpatients. However, to date, the relationship between (18)F-FDG uptake and HER2 expression has not, to our knowledge, been investigated. In this study, we aimed to investigate whether HER2 expression is associated with (18)F-FDG uptake and whether (18)F-FDG PET/CT can be used to predict the HER2 status of gastric cancer. METHODS: A retrospective analysis was performed on 64 gastric cancerpatients who had undergone (18)F-FDG PET/CT before surgical resection. Tumor SUVmax was calculated from the level of (18)F-FDG uptake. RESULTS: No significant correlation was found between SUVmax and HER2 expression in gastric cancer. However, when signet-ring cell carcinoma was excluded, SUVmax was significantly higher in the HER2-negative group than in the HER2-positive group (8.619 ± 5.878 vs. 3.789 ± 2.613, respectively; P = 0.021). Multivariate analysis indicated that SUVmax and tumor differentiation remained significantly associated with HER2 expression (P = 0.048 and P = 0.028, respectively). HER2 expression was predicted with an accuracy of 64.4% when an SUVmax cutoff of 6.2 was used. CONCLUSION: (18)F-FDG uptake by gastric cancer is associated with HER2 expression. (18)F-FDG PET/CT may be useful for predicting the HER2 status of gastric cancer and for determining the therapeutic strategy.
Authors: Ji Soo Park; Nare Lee; Seung Hoon Beom; Hyo Song Kim; Choong-Kun Lee; Sun Young Rha; Hyun Cheol Chung; Mijin Yun; Arthur Cho; Minkyu Jung Journal: Gastric Cancer Date: 2017-06-22 Impact factor: 7.370
Authors: Varun Manoharan; Soon Lee; Shanley Chong; June Yap; Nick Coupe; Robert Wilson; Neil Merrett; Weng Ng; Michael Lin Journal: Ann Nucl Med Date: 2017-03-15 Impact factor: 2.668